Kither begins dosing in COPD trial of KIT2014

Kither Biotech has begun dosing patients in a phase 1b/2a clinical trial in Australia testing KIT2014, an inhaled peptide therapy targeting moderate to severe COPD, to evaluate safety, tolerability, pharmacokinetics, and early efficacy signals.

This Wire brief sits within Fusion42's coverage of Biotech.